Kalp Kapak Ekokardiyografisi

Authors

Adnan Yamanoğlu
Hüseyin Acar

Synopsis

Heart valve diseases, which can remain asymptomatic in the early stages, may lead to heart failure and severe symptoms such as dyspnea, syncope, and hemodynamic instability as they progress. Transthoracic echocardiography (TTE) is recommended as the primary diagnostic method for evaluation and follow-up. While aortic regurgitation, aortic stenosis, mitral regurgitation, and mitral stenosis are observed in the left heart, tricuspid regurgitation, tricuspid stenosis, pulmonary regurgitation, and pulmonary stenosis affect the right heart. Staging for aortic valve pathologies relies on gray-scale and color Doppler techniques to analyze jet flow and pressure gradients. Mitral valve disorders cause volume and pressure overload in the left atrium and ventricle, with rheumatic mitral stenosis characteristically displaying the hockey-stick sign. Tricuspid and pulmonary valve lesions mostly develop secondary to left heart pathologies. Early recognition of valvular abnormalities using bedside echocardiography by non-cardiology clinicians is essential to refer patients for timely surgical intervention before irreversible systolic dysfunction occurs.

References

Chen RS, Bivens MJ, Grossman SA.Diagnosis and management of valvular heart disease in emergency medicine.Emerg Med Clin North Am. 2011 Nov;29(4):801-10.

Siegel RJ, Luo H, Makar M, Beigel R.Optimal use of echocardiography in valvular heart disease evaluation. Heart. 2015 Jun;101(12):977-86.

Long B, Koyfman A, Gottlieb M.Management of Heart Failure in the Emergency Department Setting: An Evidence-Based Review of the Literature.J Emerg Med. 2018 Nov;55(5):635-646.

Walsh K, Hoffmayer K, Hamdan MH.Syncope: diagnosis and management.Curr Probl Cardiol. 2015 Feb;40(2):51-86.

McClung JA.Native and Prosthetic Valve Emergencies. Cardiol Rev. 2016 Jan-Feb;24(1):14-8.

Nishimura RA, Otto CM, Bonow RO et al. Guidelines., 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice. basım yeri bilinmiyor: Circulation. 2017 Jun 20;135(25):e1159-e1195.

Misfeld M, Sievers HH.Heart valve macro- and microstructure.Philos Trans R Soc Lond B Biol Sci. 2007;362(1484):1421-36.

Mrsic Z, Hopkins SP, Antevil JL, Mullenix PS.Valvular Heart Disease.Prim Care. 2018 Mar;45(1):81-94.

Akinseye OA, Pathak A, Ibebuogu UN.Aortic Valve Regurgitation: A Comprehensive Review.Curr Probl Cardiol. 2018;43(8):315-334.

Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017, 2017 ESC/EACTS Guidelines for the management of valvular heart disease.Eur Heart J. ve 38(36):2739-2791.

Bonow RO, Carabello BA, Chatterjee K, et al: 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease.J Am Coll Cardiol 52: e1, 2008. [PMID:18848134].

Baumgartner H Chair, Hung J Co-Chair, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, Lancellotti P, LeFevre M, Miller F Jr, Otto CM. 2017, Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography.Eur Heart J Cardiovasc Imaging. ve 18(3):254-275.

Bakaeen FG, Rosengart TK, Carabello BA.Aortic Stenosis.Ann Intern Med. 2017;166(1):ITC1-ITC16.

Joseph J, Naqvi SY, Giri J, Goldberg S.Aortic Stenosis: Pathophysiology, Diagnosis, and Therapy.Am J Med. 2017;130(3):253-263.

Vahanian A, Iung B.Mitral regurgitation. Timing of surgery or interventional treatment.Herz. 2016;41(1):3-9. 16. Harb SC, Griffin BP.Mitral Valve Disease: a Comprehensive Review.Curr Cardiol Rep. 2017;19(8):73.

Ray R, Chambers J.Mitral valve disease.Int J Clin Pract. 2014 ;68(10):1216-20.

Nishimura RA, Vahanian A, Eleid MF, Mack MJ.Mitral valve disease--current management and future challenges.Lancet. 2016;387(10025):1324-34.

Chandrashekhar Y, Westaby S, Narula J.Mitral stenosis. Lancet. 2009 ;374(9697):1271-83.

Huttin O, Voilliot D, Mandry D, Venner C, Juillière Y, Selton-Suty C.Huttin O1, Voilliot D1, Mandry D2, Venner C1, Juillière Y1, Selton-Suty C3.Arch Cardiovasc Dis. 2016 ;109(1):67-80.

Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C.Functional tricuspid regurgitation: a need to revise our understanding.J Am Coll Cardiol. 2015 ;65(21):2331-6.

Hung J.The pathogenesis of functional tricuspid regurgitation.Semin Thorac Cardiovasc Surg. 2010 ;22(1):76-8.

Cevasco M, Shekar PS.Surgical management of tricuspid stenosis.Ann Cardiothorac Surg. 2017 ;6(3):275-282.

Shah PM, Raney AA.Tricuspid valve disease.Curr Probl Cardiol. 2008;33(2):47-84.

Fathallah M, Krasuski RA.Pulmonic Valve Disease: Review of Pathology and Current Treatment Options.Curr Cardiol Rep. 2017;19(11):108.

Calafiore AM, Gallina S, Iacò AL, Contini M, Bivona A, Gagliardi M, Bosco P, Di Mauro M. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated? a propensity score analysis. basım yeri bilinmiyor : Ann Thorac Surg., Cilt Ann Thorac Surg. 2009 Mar;87(3):698-703. doi: 10.1016/j.athoracsur.2008.11.028.

Pages

115-135

Published

November 12, 2021

License

License